Biocept Inc (BIOC) News

Form 8-K - Current report

Form 8-K - Current report

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40...

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive...

Biocept to Participate in the H.C. Wainwright Global Investment Conference

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces...

Biocept to Hold Business Update Conference Call on August 30, 2023

Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific...

Form 8-K - Current report

Biocept Reports Second Quarter 2023 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three...

Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces...

Biocept Announces the Passing of Board Chair M. Faye Wilson

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July...

Current Report Filing (8-k)

BIOCEPT INC false 0001044378 0001044378 2023-06-16 2023-06-16     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Initial Statement of Beneficial Ownership (3)

FORM 3          UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Biocept Names Antonino Morales as President and Chief Executive Officer

Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading...

Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023

Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces...

Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology

Real-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting...